RE
BCLI

RBC Europe’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

RBC Europe’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-47
Closed -$2.31K – 681
2021
Q3 		$2.31K Hold
47
– – ﹤0.01% 1114
2021
Q2 		$2.66K Hold
47
– – ﹤0.01% 1097
2021
Q1 		$2.68K Hold
47
– – ﹤0.01% 1056
2020
Q4 		$3.17K Buy
47
+20
+74% +$2.72K ﹤0.01% 1018
2020
Q3 		$6.77K Buy
+27
New +$5.53K ﹤0.01% 865
2018
Q1 		– Sell
-31
Closed -$1.83K – 1129
2017
Q4 		$1.83K Hold
31
– – ﹤0.01% 1054
2017
Q3 		$1.93K Buy
+31
New +$2.01K ﹤0.01% 1051

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RBC Europe's BCLI Position: Q4 2021 in Review

RBC Europe sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2021, closing a stake of 47 shares — an estimated $2.31K sold.

RBC Europe first reported a position in BCLI in Q3 2017 and held it in 7 quarters. The position peaked at $6.77K in Q3 2020. 43 funds tracked by Wall St. Rank hold BCLI as of Q4 2021.

  • RBC Europe reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 47 BRAINSTORM CELL THERAPUTC shares in Q4 2021, an estimated $2.31K.
  • RBC Europe first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2017 and held it in 7 quarters.
  • RBC Europe's BRAINSTORM CELL THERAPUTC position peaked at $6.77K in Q3 2020.
  • 43 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.